SCYNEXIS logo

SCYNEXISNASDAQ: SCYX

Profile

Sector:

Healthcare

Country:

United States

IPO:

02 May 2014

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$50.54 M
-73%vs. 3y high
35%vs. sector
-vs. 3y high
-vs. sector
-97%vs. 3y high
37%vs. sector
-91%vs. 3y high
62%vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$1.33-$0.05(-3.93%)

Dividend

No data over the past 3 years
$736.00 K$6.18 M
$736.00 K-$14.46 M

Analysts recommendations

Institutional Ownership

SCYX Latest News

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
globenewswire.com10 October 2024 Sentiment: POSITIVE

JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, at 11:30 A.M. ET.

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
globenewswire.com03 October 2024 Sentiment: POSITIVE

JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 taking place in Los Angeles, CA from October 16-19, 2024.

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com08 August 2024 Sentiment: POSITIVE

JERSEY CITY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2024.

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'
Seeking Alpha18 December 2023 Sentiment: POSITIVE

Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance. The company's approved product, ibrexafungerp, has been licensed to GSK with anticipated peak sales of over $500M. Ibrexafungerp commercialization and clinical development was paused due to manufacturing concerns, resulting in a 50% dip in SCYX valuation. However, the issue is expected to be resolved within few months. Considering cash runway >2 years, SCYX is sufficiently funded to resolve the issue and start having an income from milestones/royalties.

Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade)
Seeking Alpha26 September 2023 Sentiment: NEGATIVE

We downgrade Scynexis to a sell rating following the voluntary recall of antifungal pill, Brexafemme. Historical precedence suggests that manufacturing recalls can take months to resolve, and for a single-product biotech, we see further downside to the stock price. Concerns around the impact on clinical trials, partnership with GSK, and uncertainty surrounding hospital-based fungal infection trials remain a key focus/risk moving forward.

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
Zacks Investment Research04 September 2023 Sentiment: POSITIVE

SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.

WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
Newsfile Corp19 May 2023 Sentiment: POSITIVE

Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C.

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research11 May 2023 Sentiment: NEGATIVE

Scynexis (SCYX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.51 per share a year ago.

Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
Zacks Investment Research31 March 2023 Sentiment: POSITIVE

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.

Scynexis: Licensing Deal With GSK, Upgrading To A Hold Rating From A Sell
Seeking Alpha31 March 2023 Sentiment: POSITIVE

GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. GSK will pay SCYNEXIS $90 million upfront, with additional milestone payments and royalties. SCYNEXIS retains rights to other assets derived from Brexafemme.

What type of business is SCYNEXIS?

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

What sector is SCYNEXIS in?

SCYNEXIS is in the Healthcare sector

What industry is SCYNEXIS in?

SCYNEXIS is in the Drug Manufacturers - Specialty & Generic industry

What country is SCYNEXIS from?

SCYNEXIS is headquartered in United States

When did SCYNEXIS go public?

SCYNEXIS initial public offering (IPO) was on 02 May 2014

What is SCYNEXIS website?

https://www.scynexis.com

Is SCYNEXIS in the S&P 500?

No, SCYNEXIS is not included in the S&P 500 index

Is SCYNEXIS in the NASDAQ 100?

No, SCYNEXIS is not included in the NASDAQ 100 index

Is SCYNEXIS in the Dow Jones?

No, SCYNEXIS is not included in the Dow Jones index

When was SCYNEXIS the previous earnings report?

No data

When does SCYNEXIS earnings report?

The next expected earnings date for SCYNEXIS is 13 November 2024